pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA
Vera Therapeutics
Vera Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 4539 Metropolitan Ct, Frederick, Maryland 21704, US
- Founded
- 2018
- Employees
- 9
- Programs
- 25
- Drugs
- 32
- Patents
- 140
Vera Therapeutics projects
4 ClinicalTrials.gov programs sponsored by Vera Therapeutics.
Vera Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Atacicept
Vera Therapeutics
IgA Nephropathy
1 trial -
Atacicept
Vera Therapeutics
Lupus Nephritis (LN)
1 trial -
Immune Globulin 10% Intravenous Solution
Vera Therapeutics
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1 trial -
VS-6766-301
Vera Therapeutics
Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
1 trial
Frequently asked questions
How many clinical projects does Vera Therapeutics have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.